Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım

Durmus, Gunduz; KESKİN, Bengisu; CAN, Mehmet Mustafa; Kalyoncuoğlu, Muhsin; ÖZTÜRK, Semi

Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım

Muhsin KALYONCUOĞLU, (*İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardı'yolojiAnab/lim Dalı, lstanbul, Türkiye)

Semi ÖZTÜRK, (*İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardı'yolojiAnab/lim Dalı, lstanbul, Türkiye)

Gündüz DURMUŞ, (*İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardı'yolojiAnab/lim Dalı, lstanbul, Türkiye)

Bengisu KESKİN, (İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardiyoloji Anabilim Dalı, İstanbul, Türkiye)

Mehmet Mustafa CAN (*İstanbul Üniversitesi Kardiyoloji Enstitüsü, Kardı'yolojiAnab/lim Dalı, lstanbul, Türkiye)

Haseki Tıp Bülteni

12 3

Yıl: 2017 Cilt: 55 Sayı: 2 Sayfa Aralığı: 85 - 100 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım

Öz:

iskemik kalp hastalıklarının (lKH) hemen hemen yarısında ilk başvuruşekli kronik stabil anginadır. Tanı ve tedavideki son yıllardaki gelişmelererağmen, lKH hala ülkemizdeki ve sanayileşmiş toplumlardaki en önemlimorbidite ve mortalite nedeni olarak karşımıza çıkmaktadır. Kronikstabil angina tedavisinde temel hedef miyokard infarktüsü ve ölümüengelleyerek yaşam beklentisini uzatmak ve anginanın sıklığını veşiddetini azaltarak hayat kalitesini arttırmaktır. Beta blokerler, kalsiyumkanal blokerleri ve nitratlar anti-iskemik ve anti-anginal tedavinin temeltaşını oluştururken, mevcut geleneksel ajanlara rağmen dirençli anginasıolan hastalarda yeni anti--anginal ajanların kullanılması düşünülmelidir.Farmakolojik ajanların yanında hastaların tedavi planlaması içindemutlaka yaşam tarzı değişiklikleri yer almalı ve hastalar bu konudasıkı sıkıya bilgilendirilmelidir. Her ne kadar kronik stabil anginadarevaskülarizasyon tedavilerinin (perkütan koroner girişim veya koronerarter by--pass cerrahisi) mortalite ve prognoz üzerine optimal medikaltedaviye üstünlüğü gösterilememiş olsa da optimal medikal tedaviyerağmen semptomatik olan hastalarda anginayı ve anti-anginal ilaçkullanım ihtiyacını daha etkili bir şekilde azalttığı, egzersiz kapasitesinive yaşam kalitesini daha fazla iyileştirdiği gösterilmiştir. Bu yazımızdaAmerikan Kalp Cemiyeti ve Avrupa Kalp Cemiyeti tanı ve yönetimkılavuzları ışığında kronik stabil anginaya güncel yaklaşımı özetlemeyeçalıştık.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Current Approach to the Chronic Ischemic Heart Disease in the Light of the Current Diagnosis and Assessment Guidelines

Öz:

Initial presentation in almost half of the patients with chronic ischemic heart disease (IHD) is chronic stable angina. Despite recent improvements in diagnosis and treatment, IHD still appears to be the most important cause of morbidity and mortality in our country and industrialized countries. The main aim of the treatment of chronic stable angina is to increase life expectancy and to improve quality of life by reducing the frequency and severity of angina. Beta-blockers, calcium channel blockers and nitrates constitute the main stones of anti-ischemic and antianginal treatment; new antianginal agents should be considered in patients with resistant angina despite usage of traditional agents. It is essential to add lifestyle modifications to pharmacological treatment and patients should be informed firmly. Even though revascularization therapy has not been shown to be superior to the optimal medical therapy in prognosis and mortality in chronic stabil angina, it reduces angina and necessity to anti-anginal medications and improves exercise capacity and quality of life in patients who are symptomatic despite optimal medical therapy. In this review, we summarized the current approach to chronic stable angina in the light of the American College of Cardiology and European Society of Cardiology guidelines for the diagnosis and assessment of chronic stable angina.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Chockalingam A, Balaguer--Vintro |, Achutti A, et al. The World Heart Federation's white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Can Cardiol 2000;16:227--9.
Demirtaş M, Çaylı M. Kronik iskemik kalp hastalığı [Chronic ischemic heart disease]. Enar R, editör. Temel Kardiyoloji, Semiyoloji ve Kardiyovasküler Hastalıklar. Nobel Tıp Kitabevleri; 2007. Sayfa 683--713.
Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Am Coll Cardiol 2012;60:e44--e164.
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart 2013;34:2949--3003.
Critchley J, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: systematic review. JAMA 2003;290:86--97.
Hubbard R, Lewis S, Smith C, etal. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005;14:416--21.
Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am Med 2006;l 19:1080--7.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: randomized trial. Circulation 2010;121:221--9.
Schaefer EJ, Lamon--Fava S, Ausman LM, et al. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step diets. Am Clin Nutr 1997;65:823--30.
Ginsberg HN, Kris--Etherton Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998;18:441--9.
Yu--Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-- Etherton PM. Effects of the National Cholesterol Education Program's Step and Step || dietary intervention programs on cardiovascular disease risk factors: metaanalysis. Am Clin Nutr 1999;69:632--46.
Grundy SM, Becker D, Clark LT, et al. National Cholesterol Education Program Coordinating Committee. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel |||) final report. Circulation 2002;106:3143--421.
Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1--68.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR). Eur HeartJ 2016;37:2315-81.
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. Am Coll Cardiol 2009;53:l925--32.
Arnlov J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle--aged men. Circulation 2010;121:230--6.
Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all--cause mortality in large US cohort. Arch Intern Med 2010;170:1293--301.
Howley ET. Type of activity: resistance, aerobic and leisure versus occupational physical activity. Med Sci Sports Exerc 2001;33:364--9.
Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008--2010 and 2010--2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart 2011;32:1769--818.
Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta--analysis of individual data from 27 randomised trials. Lancet 2012;380:581--90.
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450--8.
Chapman MJ, Ginsberg HN, Amarenco et al. Triglyceride-- rich lipoproteins and high--density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart 2011;32:1345--61.
Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: call to action to reduce residual vascular risk in patients with dyslipidemia. Am Cardiol 2008; 02:1 K--34K.
Al Mobeirek AF, Albackr H, Al Shamiri M, Albacker TB. Review of Medical Treatment of Stable Ischemic Heart Disease. International Journal of Clinical Medicine 2014;5:249--59.
Bhatt DL, Flather MD, Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Am Coll Cardiol 2007;49:1982--8.
O'Rourke RA, O'Gara PT, Shaw LJ, Douglas JS. Diagnosis and management of patients with chronic ischemic heart disease. Fuster V, Walsh RA, O'Rourke RA, Poole--Wilson P, editors. Hurt's The Heart, 12th edition. China: The McGraw--Hill Companies; 2008. p.1474--504.
Morrow DA, Boden WE. Stable ishcemic heart disease. Mann DL, Zipes DP, Libby Bonow RO, Braunwald E, editors. Braunwald's Heart Disease, textbook of cardiovascular medicine. 10th ed. Philedelphia: Elsevier inc. 2015. p.1182-- 245.
Krishnaswamy A, Kapadia SR. Stable Angina. Griffin BF: editor. Manual of Cardiovascular Medicine. 4th ed. Philedelphia: Lippincott Williams Wilkins; 2013. p. 97--120.
Freemantle N, Cleland J, Young Mason J, Harrison J. Beta Blockade after Myocardial Infarction:Systematic Review and Meta Regression Analysis. BMJ 1999;318:1730--7.
Law MR, Morris JK, Wald NJ. Use of Blood Pressure Drugs in the Prevention of Cardiovascular Disease: Meta--Analysis of 147 Randomized Trials in the Context of Expectations from Prospective Epidemiological Studies. BMJ 2009;338:b1665. . Rehnqvist N, Hjemdahl Billing E, etal. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). EurHeart 1996;17:76--81.
Poole--Wilson PA, Lubsen J, Kirwan BA, etal. Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long--acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849--57.
ISI54 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS--4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. [No authors listed]. Lancet 1995;345:669--85.
Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI--3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6--week mortality and ventricular function after acute myocardial infarction. [No authors listed]. Lancet 1994;343:1115--22.
Henderson RA, O'Flynn N. Management of stable angina: summary of NICE guidance. Heart 2012;98:500--7.
Fox KM. European Trial on Reduction of Cardiac Events among Patients with Stable Coronary Artery Disease: Randomized, Double--Blind, Placebo--Controlled, Multicenter Trial (the EUROPA Study). Lancet 2003;362:782--8.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies J, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin--Converting--Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High--Risk Patients. Engl Med 2000;342:145--53.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). [No authors listed]. Lancet. 1994 Nov l9;344:l383--9.
Sacks FM, Pfeffer MA, Moye LA, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholestrol Levels. Engl Med 1996;335:1001--9.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. The Long--Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Engl Med 1998;339:1349--57.
Collins R, Armitage J, Parish S, Sleigh Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholestrol Lowering with Simvastatin in 5963 with Diabetes: Randomized Placebo--Controlled Trial. Lancet 2003;361:2005--16.
Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy--Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. EnglJ Med 2004;350:1495--504.
LaRosa JC, Grundy SM, Waters DD. Treating to New Targets (TNT). Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. Engl Med 2005;352:1425-- 35.
Stone N, Robinson JG, Lichtenstein AH, et al. 2013 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Am Coll Cardiol 2014;63:2889--934.
Fihn SD, Blankenship JC, Alexander KP et al. 2014 ACC/ AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. JACC 2014;64:192949.
Chaitman BR, Skettino SL, Parker JO, et al. Wolff AA; MARISA Investigators. Anti--Ischemic Effects and Long--Term Survival during Ranolazine Monotherapy in Patients with Chronic Severe Angina. Am Coll Cardiol 2004;43:1375--82.
Chaitman BR, Pepine CJ, Parker JO, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: randomized controlled trial. JAMA 2004;291:309--16.
Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Am Coll Cardiol 2006;48:566--75.
Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of Ranolazine in Patients with Type Diabetes Mellitus and Chronic Stable Angina: Results from the TERISA Randomized Clinical Trial (Type Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina). Am Coll Cardiol 2013;61:2038--45.
Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of Ronalizine in Patients with Chronic Angina; Observations from the Randomized Double--Blind, Placebo--Controlled MERLIN-- TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non--ST--Segment Elevation Acute Coronary Syndromes) 36 Trial. Am Coll Cardiol 2009;53:1510--6.
Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. INITIATIVE Investigators. Efficacy of Ivabradine, New Selective If Inhibitor, Compared with Atenolol in Patients with Chronic Stable Angina. Eur HeartJ 2005;26:2529--36.
Ruzyllo WR, Tendera M, Ford I, Fox KM. Antianginal Efficacy and Safety of Ivabridine Compared with Amlopidine in Patients with Stable Effort Angina Pectoris: 3--Month Randomised, Double--Blind, Multicenter, Noninferiority Trial. Drugs 2007;67:393405.
Tardif JC, Ponikowski Kahan T. ASSOCIATE Study Investigators. Efficacy of the If Current Inhibitor Ivabradine in Patients with Chronic Stable Angina Receiving Beta--Blocker Therapy: 4--Month, Randomized, Placebo--Controlled Trial. Eur HeartJ 2009;30:540--8.
Fox K, Ford |, Steg PG, Tendera M, Ferrari R. BEAUTIFUL Investigators. Ivabradine for Patients with Stable Coronary Artery Disease and Left--Ventricular Systolic Dysfunction (BEAUTIFUL): Randomized, Double--Blind, Placebo-- Controlled Trial. Lancet 2008;372:807--16.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. BEAUTIFUL Investigators. Relationship between Ivabridine Treatment and Cardiovascular Outcomes in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction with Limiting Angina: Subgroup Analysis of the Randomized Controlled BEAUTIFUL Trial. Eur Heart 2009;30:2337-45.
IONA Study Group. Effect of Nicorandil on Coronary Events in Patients with Stable Angina: The Impact of Nicorandil in Angina (IONA) Randomized Trial. Lancet 2002;359:1269--75.
Izumiya Y, Kojima S, Kojima S, et al. Long--term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011;214:415--21.
Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes Trimetazidine: new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br Clin Pharmacol 1994;37:279--88.
El--Kady T, El--Sabban K, Gabaly M, Sabry A, Abdel--Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: 24--month study. Am Cardiovasc Drugs 2005;5:271--8.
Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in randomized, placebo--controlled, multicenter study. Am Ther 2005;12:35--42.
Cross HR. Trimetazidine for stable angina pectoris. Expert Opin Pharmacother 2001 ;2:857--75.
Vicari RM, Chaitman B, Keefe D, et al. Fasudil Study Group. Efficacy and Safety of Fasudil in Patients with Stable Angina. Double Blind Placebo--Controlled, Phase Trial. Am Coll Cardiol 2005;46:1803-11.
Sarı AN, Fırat SŞ, Tunçtan B. Rho Kinaz ve Kardiyovasküler Hastalıklar. Mersin Univ Sağlık Bilim Derg 2010;3:l--7.
Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of High Dose Allopurinol on Exercise Capacity in Patients with Chronic Stable Angina. Lancet 2010;375:2161--7.
Rajendra NS, Ireland S, George J, Belch J, Lang CC, Struthers AD. Mechanistic Insights into the Therapeutic Use of High Dose Allopurinol in Angina Pectoris. Am Coll Cardiol 2011;58:820--8.
Wagner F, Gohlke--Barwolf C, Trenk D, Jahnchen E, Roskamm H. Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-- term administration in stable angina pectoris. Eur Heart 1991;12:994--9.
Streel B, Ceccato A, Peerboom C, Zimmer C, Sibenaler R, Maes Determination of molsidomine and its active metabolite in human plasma using liquid chromatography with tandem mass spectric detection. Chromatogr 1998;819:113--23. Schönafinger K. NO prodrugs. 1999;54:316--20.
Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication--a double--blind, placebo--controlled study. Intern Med 1992;231:261--7.
van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. double--blind, randomized, controlled trial. Circulation 1994;90:1194--9.
Sloth--Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am Surg 1991 ;1 62:122--5.
Knudtson ML, Wyse DG, Galbraith PD, et al. Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators. Chelation therapy for ischemic heart disease: randomized controlled trial. JAMA 2002;287:481-- 6.
Lamas GA, Goertz C, Boineau R, et al. TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013;309:1241--50.
Authors/Task Force members, Windecker S, Kolh Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology7. (ESC) and the European Association for Cardio--Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur HeartJ 2014;35:2541--619.
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574--651. Heterocyclic Farmaco
Blumenthal RS, Cohn G, Schulman Medical Therapy Versus Coronary Angioplasty in Stable Coronary Artery Disease: Critical Review of the Literature. Am Coll Cardiol 2000;36:668--73.
Hueb WA, Bellotti G, de Oliveira SA, et al. The medicine, angioplasty or surgery study (MASS): prospective, randomized trial of medical therapy balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. Am Coll Cardiol 1995;26:1600--5.
Hueb W, Lopes N, Gersh BJ, et al. Ten--Year Follow--Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS |I); Randomized Controlled Clinical Trial of Therapeutic Strategies for Multivessel Coronary Artery Disease. Circulation 2010;122:949--57.
Coronary angioplasty versus medical therapy for angina: the second randomized intervention treatment of angina (RITA-- 2) trial. RITA--2 trial participants. [No authors listed]. Lancet 1997;350:461--8.
Boden WE, O'Rouke RA, Toe KK, et al. COURAGE Trial Research Group. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. Engl Med 2007;356:1503-- 16.
Hochman JS, Lamas GA, Buller CE, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. Engl Med 2006;355:2395-- 407.
Frye RL, August Brooks MM, et al. The BARI 2D Study Group. Randomized Trial of Therapies for Type Diabetes and Coronary Artery Disease. Engl Med 2009;360:2503-- 15.
Velazquez EJ, Lee KL, Deja MA, et al. STICH Investigators. Coronary--Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. Engl Med 2011;364:1607--16.
De Bruyne B, Pijls NH, Kalesan B, et al. FAME Trial Investigators. Fractional Flow Reserve--Guided PCI versus Medical Therapy in Stable Coronary Disease. Engl Med 2012;367:991--1001.
Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: systematic review and meta--analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5:476-- 90.
Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary--artery bypass7. grafting for severe coronary artery disease. Engl Med 2009;360:961--72.

APA	Kalyoncuoğlu M, ÖZTÜRK S, Durmus G, KESKİN B, CAN M (2017). Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. , 85 - 100.
Chicago	Kalyoncuoğlu Muhsin,ÖZTÜRK Semi,Durmus Gunduz,KESKİN Bengisu,CAN Mehmet Mustafa Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. (2017): 85 - 100.
MLA	Kalyoncuoğlu Muhsin,ÖZTÜRK Semi,Durmus Gunduz,KESKİN Bengisu,CAN Mehmet Mustafa Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. , 2017, ss.85 - 100.
AMA	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. . 2017; 85 - 100.
Vancouver	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. . 2017; 85 - 100.
IEEE	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M "Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım." , ss.85 - 100, 2017.
ISNAD	Kalyoncuoğlu, Muhsin vd. "Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım". (2017), 85-100.

APA	Kalyoncuoğlu M, ÖZTÜRK S, Durmus G, KESKİN B, CAN M (2017). Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. Haseki Tıp Bülteni, 55(2), 85 - 100.
Chicago	Kalyoncuoğlu Muhsin,ÖZTÜRK Semi,Durmus Gunduz,KESKİN Bengisu,CAN Mehmet Mustafa Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. Haseki Tıp Bülteni 55, no.2 (2017): 85 - 100.
MLA	Kalyoncuoğlu Muhsin,ÖZTÜRK Semi,Durmus Gunduz,KESKİN Bengisu,CAN Mehmet Mustafa Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. Haseki Tıp Bülteni, vol.55, no.2, 2017, ss.85 - 100.
AMA	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. Haseki Tıp Bülteni. 2017; 55(2): 85 - 100.
Vancouver	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım. Haseki Tıp Bülteni. 2017; 55(2): 85 - 100.
IEEE	Kalyoncuoğlu M,ÖZTÜRK S,Durmus G,KESKİN B,CAN M "Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım." Haseki Tıp Bülteni, 55, ss.85 - 100, 2017.
ISNAD	Kalyoncuoğlu, Muhsin vd. "Güncel Tedavi Kılavuzları Işığında Kronik İskemik Kalp Hastalığı Tedavisine Yaklaşım". Haseki Tıp Bülteni 55/2 (2017), 85-100.